上海君實生物醫藥科技股份有限公司
Shanghai Junshi Biosciences Co., Ltd.*
( 於中華人民共和國註冊成立的股份有限公司 )
股份代號 : 1877
2020
中期報告
* 僅供識別
2
4
8
27
45
46
48
50
51
53
74
2
2
1
2
Roy Steven Herbst
Roy Steven Herbst
1
2
3
36
58 2 13
16
183 54
H
2
1
183 54
1
3
H 01877
A 688180
871,276,500 688,530,000 A
182,746,500 H
H
200 H
www.junshipharma.com
1
2020 7 24
2
2020 6 19
3
2020 6 19
4
2020 575 2019 86%
90%
2020 709 2019 369 92%
(ADC) JS016
2020 6 2019 11% 2,026
593 2019 105%
(license-in)
21 19 2
15 2
NDA
UC NPC NSCLC EC
SCLC TNBC HCC GC RCC
5
– 2020 3 FDA
– 2020 4 5
2020
7
– 2020 6 Merck KGaA
TAB004/JS004 BTLA
2020 4 I I
JS005 IL-17A 2020 5 I
I
2020 3
JS016 SARS-CoV-2 COVID-19
– 2020 5 COVID-19
JS016
– 2020 5 JS016 SARS-
CoV-2
6
– 2020 6 JS016 I 2020 7 I
I JS016
40
Ib
II/III
JS016
18A.09 18A.11
2020 7 15 B
A A 2020 7 15
Revitope Oncology, Inc. Revitope Limited Revitope
Revitope T
T Revitope 5 TEAC
Trop2 Tub196 JS108
PARP Senaparib(IMP4297)
50%
IMP4297
7
6 30
2020 2019
%
574,932 309,306 86
484,436 268,727 80
(228,170) (110,687) 106
(708,912) (368,737) 92
(144,014) (93,315) 54
(593,273) (289,347) 105
(0.76) (0.37) 105
(0.76) (0.37) 105
2020 2019
6 30 12 31
%
2,757,015 2,511,324 10
1,809,062 1,911,116 (5)
4,566,077 4,422,440 3
830,736 828,548 –
1,336,466 605,376 121
2,167,202 1,433,924 51
2,398,875 2,988,516 (20)
8
first-in-class best-in-class
JS001 PD-1
JS002 UBP1213
IND PCSK9 BLyS TAB004/JS004
BTLA FDA NMPA
JS016
(ADC)
9
2018 12 17
2
2
JS001 PD-11
1. JS001
2. II III
JS003 PD-L1
TAB004/JS004 BTLA
JS006 TIGIT /
JS007 CTLA-4 /
JS009 /
JS011 /
JS012 /
JS101 Pan-CDK
JS104 Pan-CDK /
JS105 PI3K-α /
JS014 IL-21 /
VEGF
JS501
Trop2 -Tub196
JS108
JS002 PCSK9
JS008 /
TNF-α
UBP1211
JS005 IL-17A
UBP1213 BLyS
JS010 /
JS016 S
10
11
(license-in)
21 19
2
1 JS001 PD-1
11 IND JS001
Ib UBP1211 NDA JS002 PCSK9
II III TAB004/JS004 BTLA
BTLA I JS016
SARS-CoV-2 I
JS501 JS003 PD-L1 JS101 Pan-CDK JS005
IL-17A I UBP1213 BLyS
JS108 Trop2 Tub196
10
12
1. JS001
PD-1
2 2018 12 17
2019
(CSCO) 17.3%
57.5% 1 69.3%
13
1 30
15
1 Ib 2020 4
2020 5
2020 3 FDA
2020 6
2018 12 17
2
2
JS001 PD-11
1 JS001
2 II III
14
2. TNF-α UBP1211
UBP1211 TNF-α
NDA
3. PCSK9 JS002
JS002 PCSK9
JS002
I II
JS002
LDL-C JS002
III
4. BTLA TAB004/JS004
TAB004/JS004 (first-in-human) B T
(BTLA) BTLA
TAB004/JS004 PD-1
2019 3 FDA 2019 4 IND 2019 10 I
TAB004/JS004 2020 1 IND
2020 4 I
15
5. SARS-CoV-2 JS016
JS016 SARS-CoV-2
COVID-19 2020 5
JS016 1,000 SARS-
CoV-2 2.45
2020 6 JS016 I 2020 7
I I JS016
40
Ib
II/III
JS016
SARS-CoV-2
16
2020
2020 2020 1-6
575 86%
709 2019 92%
1.
(1) 2020 1 BTLA TAB004/JS004 NMPA
2020 4 I TAB004/JS004
NMPA FDA (IND)
TAB004/JS004
T
(2) 2020 4 NPC
PD-1
NPC NDA NPC
III JUPITER-02 (NCT03581786)
17
(3) 2020 5 UC
UC UC
(4) EGFR NSCLC III
NMPA NDA
(5)
(6) 2020 5 JS005 IL-17A I
I JS005
IL-17 IL-17A
(7) 2020 6 JS016 SARS-CoV-2
2020 7 I
JS016 JS016
18
2.
2019 92%
123% 2020 6 30 61
51 10
1 JS001 2020 2
Clinical Cancer
Research
IF 10.107
2 JS001 2020 4
Clinical Cancer POLARIS-01
Research
IF 10.107
127
(ORR) 17.3%
(DCR) 57.5% 2
(DOR)
(PFS) 3.6 (OS)
22.2 PD-L1
3 JS016 Nature 202 0 5
SARS- IF 43.070
CoV-2
(SARS-
CoV-2)
CB6
19
3.
2020 3 (JS016) JS016
SARS-CoV-2
ACE2 2020 5
JS016 JS016
2020 7 I Ib
II/III
JS016
JS016 2020
4.
A A 2020 7 15
JS004 JS001
5.
1,875 2020 6 30
325
20
1.
2020 575
a. 426 2020 254
2020
90%
b. 144 2020 5
JS016 SARS-CoV-2
COVID-19
2.
6 30
2020 2019
6,155 11,815
4,079 708
10,234 12,523
(i)
(ii) (iii)
3.
2019 6 30 2020 6 30 369
709 (i)
(ii)
(iii)
21
4.
2019 6 30 2020 6 30 111
228
5.
2019 6 30 2020 6 30 93 144
(i) (ii)
6.
2020 6 30 2019 12 31 1,214 676
H -
(i) (ii)
(iii)
2020 7 15 A
2020 6 30
13
54,838
22
(a)
6 30
2020 2019
(597,899) (289,189)
6 30
2020 2019
784,146,500 783,092,953
(b)
2018 2 23 2019 6 30
2019 6 30
2020 6 30
2018 5 14 2018 12 16
2019 1
2019 6 30
2020 6 30
23
2020 2019
6 30 12 31
10,000 –
93,416 69,345
103,416 69,345
2018 4 15 5%
2018 9
3 15%
2019 10 51
4.5479% 2020 6 30 4.2773%
2020 2 10
2.86% 2020 6 30
75
24
30 60 2019 30 45
2020 2019
6 30 12 31
0 30 115,487 96,647
31 90 117,197 60,235
91 180 8,631 534
241,315 157,416
15 60 2019 15 60
2020 2019
6 30 12 31
0 30 48,836 58,726
31 60 6,679 2,946
61 180 4,013 11,426
180 5,012 1,518
64,540 74,616
25
2020 6 30 269 4.35%
900 2019 9 12 2022 11 29
2020 6 30 800 5.23%
i) ii)
2020 6 30
2020 2019
6 30 12 31
1,725,167 1,607,916
60,644 62,425
1,785,811 1,670,341
349,919 76,891
720,000 744,896
1,069,919 821,787
2020 6 30
26
2019 7 5 2,000,000
228
2020 6 30 2019 6 30
– 227,250
2020 6 30
405 2019 12 31 427 5%
2020 3,000
100% 2020 6 30
16%
27
2020 6 30 46 73
15 6 4 5
Roy Steven Herbst
2020 6 19
2020 7 24
2020 4 26 2020 6 19
28
5
13.51B(1)
2019 9 2020 3 23
9969)) 2019 11 2020 8
2020 4 24 9926))
29
2020 6 19 2020 4 24
600100
2018
2020 4 27
2020 4 26
2020 4
27
2020 6 30 XV
XV 7 8
352
30
(1) (1) (1)
87,252,968 (L) 14.51% 11.13%
129,978,568 (L) 21.61% 16.58%
(2)
13,140,000 (L) 2.18% 1.68%
3,657,600 (L) 0.61% 0.47%
7,774,500 (L) 1.29% 0.99%
(3)
195,550,736 (L) 32.52% 24.94%
(4)
8,608,000 (L) 1.43% 1.10%
(5)
78,852,000 (L) 13.11% 10.06%
H 37,189,000 (L) 20.35% 4.74%
(5)
1. 2020 6 30 784,146,500 601,400,000 182,746,500 H
2. (i)
2017 12 25 2017 2020 6
30 2017 108,297,768
41,060,000 (ii)
2019 7 26 2019 2020 6 30
2019 21,680,800
2020 6 30 (i) 20%
4,372,144 2017 (ii)
40%
4,600,000 43,584,000 2017
86.28% 52,556,144
31
3. 2020 6 30 7,774,500 60%
86.28%
2017
4. 2020 6 30 8,608,000
5. 2020 6 30 76,590,000
2,262,000
99.99%
2020 6 30 Loyal Valley Capital Advantage Fund LP LVC Fund I Loyal Valley Capital Advantage Fund
II LP LVC Fund II LVC Renaissance Fund LP LVC Renaissance Fund LVC Fund I LVC Fund II
LVC Funds 10,106,000 H 12,127,000 H 14,956,000 H Loyal Valley Capital
Advantage Fund GP Limited LVC Fund I GP LVC Fund I Loyal Valley Capital Advantage Fund
II Limited LVC Fund II GP LVC Fund II LVC Renaissance Limited LVC Renaissance GP
LVC Renaissance Fund LVC Fund I GP LVC Fund II GP LVC Renaissance GP LVC Holdings
Limited LVC Innovate Limited LVC Bytes Limited Jovial
Champion Investments Limited Jovial Champion Investments Limited Vistra Trust
(Singapore) Pte. Limited LVC Renaissance Fund(i) Golden Valley Global Limited 20.13%
99.99%
(ii) Loyal Valley Innovation Capital
(HK) Limited 33.28% LVC
Funds 37,189,000 H
2020 6 30
XV 352
32
2020 6 30
XV 2 3
336
(1) (2) (2)
(3) (4)
41,060,000 (L) 6.83% 5.24%
154,490,736 (L) 25.69% 19.70%
(4)
43,584,000 (L) 7.25% 5.56%
151,966,736 (L) 25.27% 19.38%
(4)
4,600,000 (L) 0.76% 0.59%
190,950,736 (L) 31.75% 24.35%
(4)
4,372,144 (L) 0.73% 0.56%
191,178,592 (L) 31.79% 24.38%
(4)
4,288,400 (L) 0.71% 0.55%
191,262,336 (L) 31.80% 24.39%
(4)
3,789,720 (L) 0.63% 0.48%
191,761,016 (L) 31.89% 24.45%
(4)
3,719,504 (L) 0.62% 0.47%
191,831,232 (L) 31.90% 24.46%
(4)
2,884,000 (L) 0.48% 0.37%
192,666,736 (L) 32.04% 24.57%
(5)
21,680,800 (L) 3.61% 2.76%
87,252,968 (L) 14.51% 11.13%
30,750,000 (L) 5.11% 3.92%
(6)
76,590,000 (L) 12.74% 9.77%
(6)
78,852,000 (L) 13.11% 10.06%
(6)
76,590,000 (L) 12.74% 9.77%
(6)
76,590,000 (L) 12.74% 9.77%
33
(1) (2) (2)
(6)(8)
76,590,000 (L) 12.74% 9.77%
(8)
2,262,000 (L) 0.38% 0.29%
(7)(8)
H 37,189,000 (L) 20.35% 4.74%
Loyal Valley Capital Advantage Fund LP (7)(9)
H 10,106,000 (L) 5.53% 1.29%
Loyal Valley Capital Advantage Fund GP Limited (7)
H 10,106,000 (L) 5.53% 1.29%
Loyal Valley Capital Advantage Fund II LP(7)(10) H 12,127,000 (L) 6.64% 1.55%
Loyal Valley Capital Advantage Fund II Limited (7)
H 12,127,000 (L) 6.64% 1.55%
LVC Renaissance Fund LP (7)
H 14,956,000 (L) 8.18% 1.91%
LVC Renaissance Limited (7)
H 14,956,000 (L) 8.18% 1.91%
LVC Holdings Limited(7) H 22,233,000 (L) 12.17% 2.84%
LVC Management Holdings Limited (7)
H 22,233,000 (L) 12.17% 2.84%
LVC Bytes Limited LVC Innovate Limited) (7)
H 37,189,000 (L) 20.35% 4.74%
Jovial Champion Investments Limited (7)
H 37,189,000 (L) 20.35% 4.74%
Vistra Trust (Singapore) Pte. Limited(7) H 37,189,000 (L) 20.35% 4.74%
(9)
H 10,106,000 (L) 5.53% 1.29%
Eminent Azure Limited (9)
H 10,106,000 (L) 5.53% 1.29%
Prosperous Wealth Global Limited (9)
H 10,106,000 (L) 5.53% 1.29%
Highbury Investment Pte Ltd(10) H 18,190,000 (L) 9.95% 2.32%
H 12,127,000 (L) 6.64% 1.55%
GIC (Ventures) Pte. Ltd. (10)
H 30,317,000 (L) 16.59% 3.87%
GIC Special Investments Private Limited (10)
H 30,317,000 (L) 16.59% 3.87%
GIC Private Limited(10) H 30,317,000 (L) 16.59% 3.87%
H 13,339,000 (L) 7.30% 1.70%
H 13,339,000 (L) 7.30% 1.70%
Gaoling Fund, L.P. (11)
H 10,715,000 (L) 5.86% 1.37%
Hillhouse Capital Advisors, Ltd.(11) H 11,400,000 (L) 6.24% 1.45%
(12)
H 9,271,700 (L) 5.07% 1.18%
34
1. L S P
2. 2020 6 30 784,146,500 601,400,000 182,746,500 H
3. 2020 6 30 41,060,000 2017
2017 154,490,736
87,252,968
4. 2017 2017
5. 2019 2019
6. 2020 6 30 76,590,000
99.99%
76,590,000
2,262,000
7. 2020 6 30 Loyal Valley Capital Advantage Fund LP LVC Fund I Loyal Valley Capital Advantage Fund
II LP LVC Fund II LVC Renaissance Fund LP LVC Renaissance Fund LVC Fund I LVC Fund II
LVC Funds 10,106,000 H 12,127,000 H 14,956,000 H Loyal Valley Capital
Advantage Fund GP Limited LVC Fund I GP LVC Fund I H
Loyal Valley Capital Advantage Fund II Limited LVC Fund II GP LVC Fund II
H LVC Renaissance Limited LVC Renaissance GP LVC Renaissance Fund
H
LVC Fund I GP LVC Fund II GP LVC Holdings Limited LVC Management Holdings
Limited LVC Holdings Limited LVC Management Holdings Limited LVC Fund I LVC
Fund II H LVC Fund I GP LVC Fund II GP LVC Renaissance GP LVC Innovate
Limited LVC Bytes Limited LVC Innovate Limited Jovial Champion Investments
Limited Vistra Trust (Singapore) Pte. Limited LVC Innovate
Limited LVC Bytes Limited Jovial Champion Investments Limited Vistra Trust (Singapore) Pte. Limited
LVC Funds H
35
8.
9. 2020 630 Eminent Azure Limited Prosperous Wealth Global Limited
LVC Fund I 33.34% LVC Fund I
10,106,000 H
10. 2020 6 30 Highbury Investment Pte Ltd Highbury 18,190,000 H Highbury LVC
Fund II 90.90% LVC Fund II 12,127,000 H Highbury GIC (Ventures) Pte.
Ltd. GIC Ventures GIC Special Investments Private Limited GIC SIPL
GIC Private Limited GIC Private GIC Ventures GIC SIPL GIC Private
Highbury H
11. 2020 6 30 Hillhouse Capital Advisors, Ltd. Gaoling Fund, L.P. YHG Investment, L.P.
Gaoling Fund, L.P. YHG Investment, L.P. 10,715,000 H 685,000 H
12. 2020 6 30 CICC CICC Securities
8,871,700 H CICC Financial Trading Limited CICC Financial Trading
400,000 H CICC CICC Securities CICC Financial Trading H
17
2020 6 30 784,146,500 601,400,000 182,746,500 H
A 55.50 87,130,000 A 2020 5 8
A 2020 7 15
A
36
A
2020 7 15 A 55.50
87,130,000 A 4,836
4,497
2020 6 19 2020
A
4,645,421 A 2020 5 27 2020 7 1
2020 5 27
2020 5 8 A 2020 7 15
2018 5 14
2019 6 17 2018 2019
2019 H 2019 5 27
2020 5 11
2019 2020 2020 H
2020 4 20
37
2018 3 12 268 6,023,000
(a)
12
(b)
(c)
29
38
(d)
(e) 9.2
(f)
25% 12
5
35% 5 17
40%
17 29
(g)
H
39
2020 6 30 4,992,000 210 4,992,000
2020 6 30 0.64% 1,031,000
58 1,031,000
2020 2020
1 1 (2)
6 30 (1)
10,000 – – – – 10,000 2019 3 12
2022 12 14
2019 3 12
5,203,000 – – – 221,000 4,982,000 2022 12 14
5,213,000 – – – 221,000 4,992,000
1. 25% 12
5 35%
5 17
40% 17
29
2.
2019 5 27 2020 4 20
40
2020 7 15 87,130,000 A A
2020 7 A
18A.09 18A.11
H 2018 12 24 18A
8.05(3) 18A.12
2020 7 9 18A.09 18A.11
2020 7 15 B
2020 7 10 2020 7 13
41
H
H H 3,003
2020 6 30 320
H 2019 8 29
2019 8 2020 8 28 H
2020 8 28 2020 8 28
H 2020 6 30
2020
2019 6 30 2020
6 30
2019 12 31
4
1,952,203 65% 2,162,440 72% 2,086,005 76,435 286,672 79% 2021
12 31
1,201,356 40% 1,201,356 40% 1,186,895 14,461 104,562 43% 2021
JS001 12 31
480,542 16% 480,542 16% 466,621 13,921 134,057 20% 2021
12 31
JS004 1a
42
2020
2019 6 30 2020
6 30
2019 12 31
4
270,305 9% 480,542 16% 432,489 48,053 48,053 16% 2021
1b
12 31
750,847 25% 540,610 18% 303,478 237,132 26,895 11% 2022
12 31
1c
300,339 10% 300,339 10% 326,849 3
6,286 3
6,286 10% 2021
12 31
3,003,389 100% 3,003,389 100% 2,716,332 319,853 3
319,853 100%
1. 2019 8 2019 8
a.
b.
c.
2.
3. H 33
4.
43
2020 7 Trop2 Tub196 JS108
2020 7 21
2020 7 Revitope Revitope
T
2020 7 14
2020 8
PARP Senaparib(IMP4297)
50% IMP4297
2020 8 20 2020 8 26
2020 8
2020 20
3.10(2) 3.21
2020 6 30
44
2020 6 30
2020 8 28
*
45
*
46 73
2020 6 30
34 34 34
2410
34
2020 8 28
*
46
2020 6 30
6 30
2020 2019
3 574,932 309,306
(90,496) (40,579)
484,436 268,727
4 10,234 12,523
5 22,090 (9,468)
(44) 750
(708,912) (368,737)
(228,170) (110,687)
(144,014) (93,315)
(3,020) (160)
(22,005) (9,324)
(10,109) (8,697)
(599,514) (318,388)
6 1,615 28,889
7 (597,899) (289,499)
4,626 152
(593,273) (289,347)
47
2020 6 30
6 30
2020 2019
(597,899) (289,189)
– (310)
(597,899) (289,499)
(593,273) (289,037)
– (310)
(593,273) (289,347)
9
(0.76) (0.37)
(0.76) (0.37)
48
2020 6 30
2020 2019
6 30 12 31
10 2,026,147 1,827,868
10 198,715 179,518
6,486 6,291
11 68,204 71,224
1,022 1,022
22,205 20,590
13 330,820 335,466
103,416 69,345
2,757,015 2,511,324
274,497 180,666
12 241,315 157,416
13 616,949 352,163
17 17
14 – 6,828
14 676,284 1,214,026
1,809,062 1,911,116
15 964,513 514,639
16 349,919 76,891
22,034 13,846
1,336,466 605,376
472,596 1,305,740
3,229,611 3,817,064
49
2020 6 30
2020 2019
6 30 12 31
16 720,000 744,896
66,842 56,320
43,894 27,332
830,736 828,548
2,398,875 2,988,516
17 784,147 784,147
1,614,731 2,204,372
2,398,878 2,988,519
(3) (3)
2,398,875 2,988,516
50
2020 6 30
2020 1 1 784,147 4,143,394 37,338 – 12,535 (1,988,895) 2,988,519 (3) 2,988,516
– – – – – (597,899) (597,899) – (597,899)
– – – – 4,626 – 4,626 – 4,626
– – – – 4,626 (597,899) (593,273) – (593,273)
– – 3,632 – – – 3,632 – 3,632
2020 6 30 784,147 4,143,394 40,970 – 17,161 (2,586,794) 2,398,878 (3) 2,398,875
2019 1 1 760,310 3,775,539 21,700 (9,367) 9,357 (1,235,293) 3,322,246 (1,113) 3,321,133
– – – – – (289,189) (289,189) (310) (289,499)
– – – – 152 – 152 – 152
– – – – 152 (289,189) (289,037) (310) (289,347)
23,837 380,001 – – – – 403,838 – 403,838
H – (12,146) – – – – (12,146) – (12,146)
– – 8,066 – – – 8,066 – 8,066
2019 6 30 784,147 4,143,394 29,766 (9,367) 9,509 (1,524,482) 3,432,967 (1,423) 3,431,544
9
51
2020 6 30
6 30
2020 2019
(525,943) (660,090)
6,155 11,815
(242,716) (390,712)
(1,044) (2,179)
– (43,535)
(2,304) (520)
234 –
(10,000) (1,000)
106 4,562
– (23,310)
6,828 16,482
9,443 –
(3,744) (5,876)
– (2,900)
1,948 –
(235,094) (437,173)
H – 403,838
(7,218) (7,442)
1 (2,319) –
H – (23,297)
323,570 700,225
(75,615) (478,686)
(23,654) (8,754)
214,764 585,884
52
2020 6 30
6 30
2020 2019
(546,273) (511,379)
1,214,026 2,763,570
8,531 43,758
676,284 2,295,949
53
2020 6 30
1.
2012 12 27
2015 5 2015 8
833330 2018 12 24
1877 2020 7 15 2020 5 8
A 2020 7 15
688180
34
2.
2020 6 30
2019 12 31
54
2020 6 30
2.
(a) (b)
55
2020 6 30
2.
2020 1 1
1 8
3
9 39
7
2.1 1 8
2020 12 31
56
2020 6 30
3.
6 30
2020 2019
430,694 308,341
i 70,956 –
ii 73,282 965
574,932 309,306
(i) 2020 6 30
2020 6 30
10,000,000 70,956,000 245,000,000
2020 6 30
2020 6 30 IND
2020 6 30
(ii) (i) IND
10,328,000 73,282,000 2020 6 30
2020 6 30
57
2020 6 30
4.
6 30
2020 2019
6,155 11,815
4,079 708
10,234 12,523
(i)
(ii) (iii)
5.
6 30
2020 2019
24,177 62
(469) (33,949)
(48) –
(1,570) –
– 14,513
– 9,906
22,090 (9,468)
58
2020 6 30
6.
6 30
2020 2019
– –
– (408)
– (408)
1,615 29,297
1,615 28,889
25%
2018 11 2
15%
15%
21%
8.84%
59
2020 6 30
7.
6 30
2020 2019
849 378
43,467 18,310
(24,457) –
19,010 18,310
12,771 9,215
(1,634) (2,053)
11,137 7,162
3,336 3,480
21,189 9,324
47,415 39,629
117,319 34,825
318,851 176,430
2,737 11,167
3,632 8,066
(20,897) (21,986)
(12,848) (12,639)
291,475 161,038
8.
60
2020 6 30
9.
(a)
6 30
2020 2019
(597,899) (289,189)
6 30
2020 2019
784,146,500 783,092,953
(b)
2018 2 23 2019 6 30
2019 6 30
2020 6 30
18 2018 5 14 2018 12 16
2019 1
2019 6 30
2020 6 30
61
2020 6 30
10.
241,648,000 2019
299,033,000
1-5
31,968,000 2019 4,491,000
31,968,000 2019 4,491,000
11.
2020 2019
6 30 12 31
73,746 73,746
(4,071) (1,181)
(1,471) (1,341)
68,204 71,224
12.
30 60 2019 30 45
2020 2019
6 30 12 31
0 30 115,487 96,647
31 90 117,197 60,235
91 180 8,631 534
241,315 157,416
62
2020 6 30
13.
2020 2019
6 30 12 31
a
5,139 4,548
9,356 8,584
b 263,886 300,927
c 191,314 201,156
d
400 6,099
e
2,715 5,430
f
6,255 25,371
130,150 125,726
g 338,737 10,376
947,952 688,217
(183) (588)
947,769 687,629
616,949 352,163
330,820 335,466
947,769 687,629
63
2020 6 30
13.
(a)
(b)
(c)
(d)
(e) 2016 12 13,574,000
60%
8,144,000 15,000 8,159,000 2017 8
20% 20%
2,715,000 2019 5,430,000 2020
6 30
(f) 2020 6 30 6,255,000 2019
25,371,000 2020 6 30
130,150,000 2019 125,726,000
2021 6 30 2020 6 30
(g)
14.
2020 4 30
2020 6 30 0.05% 2.7% 2019 0.3% 3.6%
64
2020 6 30
15.
2020 2019
6 30 12 31
64,540 74,616
91,868 112,561
236,562 98,621
9,967 14,919
29,095 42,948
105,238 113,311
8,628 10,409
348,793 13,565
69,822 33,689
964,513 514,639
15 60 2019 15 60
2020 2019
6 30 12 31
0 30 48,836 58,726
31 60 6,679 2,946
61 180 4,013 11,426
180 5,012 1,518
64,540 74,616
65
2020 6 30
16.
2020 2019
6 30 12 31
801,161 746,085
268,758 75,702
1,069,919 821,787
349,919 76,891
720,000 744,896
1,069,919 821,787
(349,919) (76,891)
720,000 744,896
4.35% 5.23% 2019: 4.35% 5.23%
66
2020 6 30
17.
1.0
2019 1 1 760,310,000 760,310
H 23,836,500 23,837
2019 6 30 , 2019 12 31
2020 6 30 784,146,500 784,147
2019 1 9 19.38
16.94 23,836,500 H 461,951,000 403,838,000
23,836,500
380,001,500
18.
2018 3 12 6,023,000
9.2 2018 5 14
2018 3 12 12 25%
2018 3 12 24 35%
2018 3 12 36 40%
67
2020 6 30
18.
2019
2020 5 11
9 4
2020 2020
1 1 6 30
2018 5 14 9.20 2019 3 12 2019 3 12 2020 3 12 2020 12 15 1,303,250 (55,250) 1,248,000
2018 5 14 9.20 2020 3 12 2020 12 16 2021 3 12 2021 12 15 1,824,550 (77,350) 1,747,200
2018 5 14 9.20 2021 3 12 2021 12 16 2022 3 12 2022 12 15 2,085,200 (88,400) 1,996,800
5,213,000 (221,000) 4,992,000
1,248,000
9.2 9.2 9.2
68
2020 6 30
18.
2018 5 14
1 2 3
a 18.00 18.00 18.00
9.20 9.20 9.20
b 36.40% 31.40% 43.30%
0% 0% 0%
2.90% 3.10% 3.20%
9.11 9.47 10.34
(a)
(b)
19.
2020 2019
6 30 12 31
405,130 427,095
69
2020 6 30
20.
70
2020 6 30
20.
2020 2019
6 30 12 31
17 17
15,000 15,000
27% 2019
EV/S 24%
8.03 2019 5.44
3,000 3,000
26% 2019:
P/R&D 26%)
4.70 (2019: 4.70)
75,416 51,345 2020 2020
25% 2019:
2019 P/R&D
2019 17.96 2019
10,000 – 2020 2020 2019:
2019
71
2020 6 30
20.
2019 1 1 –
15,000
2019 6 30 15,000
2020 1 1 18,000
5 24,177
(106)
51,345
2020 6 30 93,416
72
2020 6 30
21.
(a)
6 30
2020 2019
* 7,200
* 2019
(b)
6 30
2020 2019
* – 456
73
2020 6 30
21.
(c)
6 30
2020 2019
29,988 19,881
11 431
184 316
30,183 20,628
22.
2020 7 15 2020 5 8 A
2020 7 15 87,130,000 A 688,530,000 A
688180 A 55.5
4,835,715,000
2020 8 19 IMPACT Therapeutics, Inc.*
100,000,000 50%
2020 8 3
2020 20,000,000
74
A 1.00
2020 7 15
A A
622
1.00
2020 5
8 2020
7 15 A
FDA
H 1.00
75
H H 2018 12 24
H H
IND
NDA
NMPA
2018 12 11 H
76
2020 6 30
571
2018 3
2018 5 14
2020 7 15
1.00 H
A 2020 7 15
%
*